Your browser doesn't support javascript.
loading
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.
Tanrikulu Simsek, Eda; Eskazan, Ahmet Emre; Cengiz, Mahir; Ar, Muhlis Cem; Ekizoglu, Seda; Salihoglu, Ayse; Gulturk, Emine; Elverdi, Tugrul; Ongoren Aydin, Seniz; Senem Demiroz, Ahu; Buyru, Ayse Nur; Baslar, Zafer; Ozbek, Ugur; Ferhanoglu, Burhan; Aydin, Yildiz; Tuzuner, Nukhet; Soysal, Teoman.
Afiliación
  • Tanrikulu Simsek E; Division of Medical Oncology, Department of Internal Medicine, Pendik Training and Research Hospital, Marmara University, Istanbul, Turkey.
  • Eskazan AE; Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Cengiz M; Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Ar MC; Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Ekizoglu S; Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Salihoglu A; Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Gulturk E; Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Elverdi T; Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Ongoren Aydin S; Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Senem Demiroz A; Department of Pathology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Buyru AN; Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Baslar Z; Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Ozbek U; Department of Genetics, Institute of Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey.
  • Ferhanoglu B; Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Koc University, Istanbul, Turkey.
  • Aydin Y; Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Tuzuner N; Department of Pathology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Soysal T; Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
J Clin Pathol ; 69(9): 810-6, 2016 Sep.
Article en En | MEDLINE | ID: mdl-26811428
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Reticulina / Médula Ósea / Fibrosis / Leucemia Mielógena Crónica BCR-ABL Positiva / Mesilato de Imatinib / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Pathol Año: 2016 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Reticulina / Médula Ósea / Fibrosis / Leucemia Mielógena Crónica BCR-ABL Positiva / Mesilato de Imatinib / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Pathol Año: 2016 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Reino Unido